JAMA Network
About The Study: Although Canada is not the largest supplier of medications to the U.S., tariffs could raise costs and strain supply chains. This study estimates that $3 billion in U.S. pharmaceuticals depend on Canadian manufacturing, with 25% tariffs adding $750 million in cost. Although the Inflation Reduction Act provisions limit cost pass-through to some payers (i.e., Medicare), manufacturers may still adjust production or alter distribution, increasing supply chain fragility.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
